Romain De Jorna

Paris, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Accelerating biosimilar adoption by empowering hospital pharmacists: a dialogue between emerging markets and European hospital pharmacists.

Accelerating biosimilar adoption by empowering hospital pharmacists: a dialogue between emerging markets and European hospital pharmacists.

Journal: European journal of hospital pharmacy : science and practice

Published: August 05, 2026

Correction: Can modified lymphodepletion before tisagenlecleucel improve outcome in high-risk patients with large B-cell lymphoma?

Correction: Can modified lymphodepletion before tisagenlecleucel improve outcome in high-risk patients with large B-cell lymphoma?

Journal: Bone marrow transplantation

Published: March 02, 2026

Can modified lymphodepletion before tisagenlecleucel improve outcome in high-risk patients with large B-cell lymphoma?

Can modified lymphodepletion before tisagenlecleucel improve outcome in high-risk patients with large B-cell lymphoma?

Journal: Bone marrow transplantation

Published: June 20, 2025

Can modified lymphodepletion before tisagenlecleucel improve outcome in high-risk patients with large B-cell lymphoma?

Can modified lymphodepletion before tisagenlecleucel improve outcome in high-risk patients with large B-cell lymphoma?

Journal: Bone marrow transplantation

Published: June 20, 2025

The French Experience of Pharmacists and CAR T-Cells: A Study of the French Society of Oncology Pharmacy (SFPO).

The French Experience of Pharmacists and CAR T-Cells: A Study of the French Society of Oncology Pharmacy (SFPO).

Journal: Hematological oncology

Published: May 11, 2025

The pharmaceutical circuit of Advanced Therapy Medicinal Products-guidelines of the French Society for Oncology Pharmacy.

The pharmaceutical circuit of Advanced Therapy Medicinal Products-guidelines of the French Society for Oncology Pharmacy.

Journal: Cytotherapy

Published: February 24, 2025

Success of donor-derived CAR-T cells after failure of autologous CD19 CAR-T cells (tisagenlecleucel) in B-cell acute lymphoblastic leukaemia.

Success of donor-derived CAR-T cells after failure of autologous CD19 CAR-T cells (tisagenlecleucel) in B-cell acute lymphoblastic leukaemia.

Journal: British journal of haematology

Published: March 20, 2024

Real-world characteristics of T-cell apheresis and clinical response to tisagenlecleucel in B-cell lymphoma.

Real-world characteristics of T-cell apheresis and clinical response to tisagenlecleucel in B-cell lymphoma.

Journal: Blood advances

Published: January 13, 2022

Advanced therapy medicinal products: Regulatory framework, hospital and pharmaceutical circuits in Europe and France.

Advanced therapy medicinal products: Regulatory framework, hospital and pharmaceutical circuits in Europe and France.

Journal: Therapie

Published: June 29, 2021

Effect of early granulocyte-colony-stimulating factor administration in the prevention of febrile neutropenia and impact on toxicity and efficacy of anti-CD19 CAR-T in patients with relapsed/refractory B-cell lymphoma.

Effect of early granulocyte-colony-stimulating factor administration in the prevention of febrile neutropenia and impact on toxicity and efficacy of anti-CD19 CAR-T in patients with relapsed/refractory B-cell lymphoma.

Journal: Bone marrow transplantation

Published: June 29, 2021

CAR-T cells gene therapy medicines: Regulatory status and pharmaceutical circuits in Europe and France

CAR-T cells gene therapy medicines: Regulatory status and pharmaceutical circuits in Europe and France

Journal: Bulletin du cancer

Published: January 22, 2021

Showing 1-11 of 11

Last Updated: 09/26/2026